DLBCL: Clinical Trials

5 trials for DLBCL, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 unknown. 5 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Unknown 5
Phase 11Unknown 1

Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression
Selinexor combined with Prednisone, Etoposide, and Lenalidomide - DLBCL
Phase 1 / Phase 2UnknownThe Affiliated Hospital of Qingdao University672022-10-012022-08-19
Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma
Orelabrutinib and Gemox - DLBCL
Phase 2UnknownSun Yat-sen University772022-07-012022-07-08
Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL
Camrelizumab - Primary Extranodal Lymphoma, DLBCL
Phase 2UnknownSun Yat-sen University302022-06-012022-04-07
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
Ibrutinib Combined With Rituximab - DLBCL, MYD88 Gene Mutation
Phase 2UnknownChinese Academy of Medical Sciences202021-10-012021-08-06
R2-CHOP in Untreated DEL-DLBCL:An Open-lable,Multicenter,Phase II Study
R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide,hydroxyldaunorubicin,Vincristine,Prednisone)) - DLBCL
Phase 2UnknownSun Yat-sen University802021-04-102021-04-13

Narrower conditions

Recurrence (2)  ·  Lymphoma (1)

Broader conditions

Disease Attributes (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Hemic and Lymphatic Diseases (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Lymphatic Diseases (1)  ·  Lymphoproliferative Disorders (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)

Interventions

Prednisone (2)  ·  Rituximab (2)  ·  Cyclophosphamide (1)  ·  Doxorubicin (1)  ·  Etoposide (1)  ·  Lenalidomide (1)  ·  Vincristine (1)  ·  camrelizumab (1)  ·  orelabrutinib (1)

Sponsors

Sun Yat-sen University (3)  ·  Chinese Academy of Medical Sciences (1)  ·  The Affiliated Hospital of Qingdao University (1)

Countries

China (2)

Top investigators

Huiqiang Huang, professor (1)  ·  Yuankai Shi, M.D. (1)  ·  Zhiming Li, Dr. (1)